Effects of MYCN Antisense Oligonucleotide Administration on Tumorigenesis in a Murine Model of Neuroblastoma
Authors:
- Andy J. ChengACAndy J. Cheng
- Janice MadafiglioJMJanice Madafiglio
- Maria KavallarisMKMaria Kavallaris
- Mario MiliMMMario Mili
- Glenn M. MarshallGMGlenn M. Marshall
- William A. WeissWWWilliam A. Weiss
- Levon M. KhachigianLevon M. Khachigian
- Murray D. NorrisMNMurray D. Norris
- Michelle HaberMHMichelle Haber
Open Access
- 16 September 2003
- journal article
- research article
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 95 (18) , 1394-1403
Abstract
Background: Human MYCN (hMYCN) oncogene amplification is a powerful predictor of treatment failure in childhood neuroblastoma, and dysregulation of hMYCN protein expression appears to be critically involved in the pathogenesis of this disease. We used hMYCN antisense (AS) oligonucleotides to investigate, both in vitro and in vivo, the therapeutic potential of inhibiting hMYCN expression. Methods: We transiently transfected human neuroblastoma IMR-32 cells, which have an amplified hMYCN gene, with fluorescently labeled hMYCN AS or scrambled (SCR) control oligonucleotides and used fluorescence-activated cell sorting to enrich for cell populations containing different levels of the oligonucleotides. We used fluorescence immunocytochemistry or reverse transcription polymerase chain reaction to assay gene expression levels and trypan blue exclusion to assay growth inhibition in the cell populations. We examined the effects of continuous treatment for 6 weeks with AS or SCR oligonucleotides via subcutaneously implanted microosmotic pumps on tumor growth in a transgenic mouse model of hMYCN-induced neuroblastoma (n = 20 mice per group). All statistical tests were two-sided. Results: IMR-32 cells treated with AS oligonucleotides had approximately half as much hMYCN protein and cell proliferation as either SCR oligonucleotide–transfected or mock-transfected controls; the differences were statistically significant. Transgenic mice treated with AS oligonucleotides had lower tumor incidence and statistically significantly lower tumor mass than SCR-treated or untreated control mice. Compared with control treatments, AS oligonucleotide treatment in vitro and in vivo was associated with decreased expression of hMYCN and putative hMYCN target genes but not with that of closely related genes. Several AS oligonucleotide–treated mice developed tumors contralateral to the site of oligonucleotide administration, whereas SCR oligonucleotide–treated or untreated mice displayed bilateral tumor growth. Conclusions: Decreased expression of hMYCN protein is achievable with the use of AS oligonucleotide treatment, even in the presence of hMYCN oncogene amplification. Antisense strategies targeting the hMYCN oncogene in vivo decrease mouse neuroblastoma tumorigenesis. Investigation of their clinical effect in children with neuroblastoma is warranted.Keywords
This publication has 33 references indexed in Scilit:
- Expression of N-myc andMRP genes and their relationship to N-myc gene dosage and tumor formation in a murine neuroblastoma modelMedical and Pediatric Oncology, 2000
- Structural, mechanistic and clinical aspects of MRP1Biochimica et Biophysica Acta (BBA) - Biomembranes, 1999
- Altered expression of the MYCN oncogene modulates MRP gene expression and response to cytotoxic drugs in neuroblastoma cellsOncogene, 1999
- Involvement of Myc targets in c-myc and N-myc induced human tumorsOncogene, 1998
- Evidence that the MYCN oncogene regulates MRP gene expression in neuroblastomaEuropean Journal of Cancer, 1997
- Targeted expression of MYCN causes neuroblastoma in transgenic miceThe EMBO Journal, 1997
- The role of multidrug resistance-associated protein (MRP) expression in multidrug resistanceAnti-Cancer Drugs, 1997
- Association of Multiple Copies of the N-mycOncogene with Rapid Progression of NeuroblastomasNew England Journal of Medicine, 1985
- Human N-myc gene contributes to neoplastic transformation of mammalian cells in cultureNature, 1985
- Amplification of N- myc in Untreated Human Neuroblastomas Correlates with Advanced Disease StageScience, 1984